The international standard of care for slowing the progression of CKD recommends the blockade of the renin-angiotensin-aldosterone system (RAAS) with angiotensin-converting enzyme inhibitors, angiotensin II receptor type 1 (AT1) antagonists, or direct renin blockers. This evidence concerns the gene AGTR1 and chronic kidney disease.